分子診断、回路鎮静モジュレーター、および制御された神経可塑性剤：精密精神神経治療における新たな戦略

New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches form a convergent framework linking molecular diagnostics, targeted circuit modulation, and scalable affective therapeutics.